Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Provention Bio Inc is a biotechnology business based in the US. Provention Bio shares (PRVB) are listed on the NASDAQ and all prices are listed in US Dollars. Provention Bio employs 59 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $4.29 |
|---|---|
| 52-week range | $4.36 - $15.98 |
| 50-day moving average | $6.17 |
| 200-day moving average | $6.85 |
| Wall St. target price | $15.64 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.97 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.29 from 2022-01-20
| 1 week (2022-01-13) | -7.54% |
|---|---|
| 1 month (2021-12-18) | N/A |
| 3 months (2021-10-22) | -30.92% |
| 6 months (2021-07-22) | -30.36% |
| 1 year (2021-01-22) | -71.81% |
|---|---|
| 2 years (2020-01-22) | -75.26% |
| 3 years (2019-01-22) | 79.50% |
| 5 years (2017-01-18) | N/A |
| Revenue TTM | $678,000 |
|---|---|
| Gross profit TTM | $0 |
| Return on assets TTM | -49.38% |
| Return on equity TTM | -89.93% |
| Profit margin | 0% |
| Book value | $2.12 |
| Market capitalisation | $293.4 million |
TTM: trailing 12 months
We're not expecting Provention Bio to pay a dividend over the next 12 months.
Over the last 12 months, Provention Bio's shares have ranged in value from as little as $4.36 up to $15.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Provention Bio's is 2.7244. This would suggest that Provention Bio's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Provention Bio, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which has completed Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co. , Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.